Clinical Trial Update: Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating HLX10 with trastuzumab and chemotherapy as first-line treatment for HER2-positive recurrent/metastatic gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• HLX10
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: UNKNOWN